2018•Value in Health Regional IssuesRequires access

Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma

Jung-Chen Ho, Meng-Lun Hsieh, Po‐Heng Chuang, Vivian Chia-Rong Hsieh

Open publisher page 9 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Sorafenib, Medicine, Hepatocellular carcinoma, Combination therapy, Oncology, Quality-adjusted life year, Internal medicine, Cost-effectiveness analysis

Back to paper search Browse research topics Original source

Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma — Research Paper | ScholarLens